Vijay Yadav’s team at a leading pharma firm reanalyzes taurine supplementation trials in murine and non-human primate models, employing controlled biomarker profiling. They compare new findings against initial positive reports, revealing that taurine’s purported longevity effects may not translate into meaningful healthspan or lifespan improvements.

Key points

• Controlled taurine supplementation trials in mice and non-human primates monitored aging biomarkers.
• Multi-parametric evaluation assessed mitochondrial function, inflammation, and senescence.
• Comparative data reveal negligible healthspan or lifespan extension, challenging initial findings.

Why it matters: These findings recalibrate expectations for taurine as a geroprotective supplement, underscoring the need for robust preclinical validation.